What is Cipla Limited (CIPLA) share price today?

Cipla Limited (CIPLA) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/CIPLA for the latest live price, technical analysis, and AI-powered insights.

How to analyse CIPLA stock?

VestAI provides comprehensive CIPLA stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Cipla Limited in?

Cipla Limited (CIPLA) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Cipla Limited

Name: Cipla Limited (CIPLA) Financial Metrics
Creator: VestAI
License: https://www.vestai.io/terms

CIPLA

NSE· Healthcare

₹1,458.80

-1.20 (-0.08%)

52W Low · ₹1,165.7052W High · ₹1,673.00

Mid Range

Market Cap

₹119011.76L Cr

Volume

9.74L

Prev Close

₹1,460.00

ISIN

INE059A01026

Orion Score

Fundamentals-based quality & risk · not a recommendation

70/100

Quality

Cipla Limited scores 70/100 (Quality) on the Orion Score — strong business quality (76), moderate growth (55), strong balance-sheet safety (91) and fair valuation (42). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 1.0× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 3/9Altman Z Safe(10.05)Beneish M Clean(-2.51)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

43/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.02x — lean balance sheet

QUALITY

Average

ROCE 13.7% — decent returns

MOMENTUM

Bullish

RSI 56.8 — strong momentum

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q1 FY2027

P/E Ratio: 35.34
ROCE: 13.66%
ROE (1Y): 11.74%
D/E Ratio: 0.02x
OPM: 12.55%
TTM EPS: ₹41.69
Dividend Yield: 88.00%
Qtrly Sales: ₹7,077.02 Cr
Qtrly Profit: ₹789.05 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q1 2027	₹7,077.02	₹789.05	12.6%	₹9.76
Q4 2026	₹6,464.26	₹554.64	9.5%	₹6.86
Q3 2026	₹6,962.97	₹675.8	14.0%	₹8.36
Q1 2026	₹6,837.04	₹1,297.62	22.3%	₹16.06
Q4 2025	₹6,597.72	₹1,221.84	18.6%	₹15.12

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2025	₹27,145.4	₹5,272.52	₹7,860.28	22.6%
FY 2024	₹25,446.63	₹4,121.55	₹6,824.05	21.1%
FY 2023	₹22,473.18	₹2,801.91	₹5,152.1	17.9%
FY 2022	₹21,623.36	₹2,516.75	₹4,588.2	16.5%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
CIPLA ★	₹1,19,012 Cr	35.34	13.66%	11.74%	0.02x	12.55%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹90,921 Cr	26.18	12.55%	9.93%	0.21x	15.11%
ASTERDMAster DM Quality	₹71,665 Cr	109.91	8.93%	10.07%	0.46x	13.98%
ABBOTINDIAAbbott India Limited	₹59,073 Cr	38.07	36.31%	34.46%	0.04x	27.01%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹37,387.04	₹32,717.82	₹29,463.28	₹27,101.12
Equity	₹31,193.45	₹26,706.43	₹23,407.78	₹20,841.69
Total Debt	₹438.19	₹559.41	₹803.12	₹1,055.78
Cash	₹588.69	₹640.07	₹627.63	₹677.74
Net Debt	—	—	—	₹146.4
Working Capital	₹17,804.56	₹14,195.64	₹12,165.28	₹9,814.33

Shareholding Pattern

Q1 FY2027

Promoter

34.57%

FII

24.32%

DII

19.9%

Public

21.21%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	34.57% ↑	24.32% ↑	19.9% ↑	21.21% ↓
Q4 FY2026	30.96% ↑	23.45% ↓	19.19% ↓	26.4% ↑
Q3 FY2026	29.22%	23.93% ↓	30.45% ↑	16.12% ↑
Q2 FY2026	29.22% ↑	24.54% ↓	29.98% ↑	15.99% ↓
Q1 FY2026	29.19%	25.24% ↓	28.98% ↑	16.3% ↓
Q4 FY2025	29.2%	26.28% ↓	27.89% ↑	16.36% ↓
Q3 FY2025	29.19% ↓	26.65% ↓	27.49% ↑	16.43% ↑
Q2 FY2025	30.93%	28.8%	23.95%	16.11%

Corporate Actions

Ex-Date	Action	Details
2026-06-05	DIVIDEND	Dividend - Rs 13 Per Share

Funds Holding This Stock

256 mutual fund schemes

ICICI Prudential Nifty Pharma Index Fund Direct GrowthICICI_PRUDENTIAL

8.83%

₹11 Cr

DSP Healthcare Fund Direct GrowthDSP

7.68%

₹254 Cr

DSP Nifty Healthcare Index Fund Direct GrowthDSP

7.56%

₹2 Cr

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI_PRUDENTIAL

7.45%

₹481 Cr

Bandhan Healthcare Fund Direct GrowthIDFC

6.76%

₹21 Cr

Nippon India Pharma Fund Direct GrowthRELIANCE

6.16%

₹532 Cr

Bandhan BSE Healthcare Index Fund Direct GrowthIDFC

5.39%

₹1 Cr

SBI Equity Minimum Variance Fund Direct GrowthSBI

5.26%

₹11 Cr

Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct GrowthEDELWEISS

5.24%

₹9 Cr

Tata India Pharma & Healthcare Fund Direct GrowthTATA

5.18%

₹72 Cr

Analyse CIPLA with Orion AI

Ask: "Is Cipla Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Cipla Limited (CIPLA) Stock

Cipla Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE059A01026. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.